Crysvita

Background

Recombinant fully human monoclonal IgG1 antibody

Approved applications

Crysvita has received conditional marketing authorization in Europe for the treatment of X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons, and an application for the expanded use in adults with XLH is currently under review by the European Medicines Agency (EMA)

Therapeutic Area

X-linked hypophosphatemia

Acquisition Date

Dec 2019

Marketer

Seller